alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Unassociated Document


     

    Exhibit
10.13

    


    Power
of Attorney

    


    I, Wei Gao, a citizen of the People’s
Republic of China (the “PRC”), ID card No. 110108197910135427, hereby
irrevocably grant a power of attorney in favor of Oriental Intra-Asia
Entertainment (China) Limited to exercise powers and rights during the term of
this Power of Attorney in connection with the followings:

    


     Oriental Intra-Asia Entertainment
(China) Limited is authorized to have full power to excise on my behalf all
voting rights as a shareholder at the shareholders’ meetings of China TransInfo
Technology Group Co., Ltd. (the “Company”) that having been given to me by law
and by the Articles of Association of the Company, including but not limited to,
the voting rights regarding the sale or transfer of all or part of the equity of
the Company held by myself and acting as my authorized representative at the
shareholders’ meeting of the Company to designate and appoint the directors of
the Company.

    


    Unless
otherwise the Operating
Agreement jointly executed by the Company, Shudong Xia, Zhiping Zhang,
Zhibin Lai, myself and Oriental Intra-Asia Entertainment (China) Limited is
earlier terminated for any reasons, the term of this Power of Attorney is ten
(10) years commencing from the execution date of this Power of
Attorney.  This Power of Attorney is executed in English.

     

    
      
        
          
            
              	
                            
                        /s/
      Wei Gao

                      

                    	 
	 	 
	
                      Wei
      Gao

                    	 
	 
      	 
	
                      February
      3, 2009
12
Anthony Cardell HAYNES, petitioner, v. Rick THALER, Director, Texas Department of Criminal Justice, Correctional Institutions Division.

No. 12-6760.

Supreme Court of the United States

June 3, 2013.

On petition for writ of certiorari to the United States Court of Appeals for the Fifth Circuit. Motion of petitioner for leave to proceed *in forma pauperis* and petition for writ of certiorari granted. Judgment vacated, and case remanded to the United States Court of Appeals for the Fifth Circuit for further consideration in light of *Trevino v. Thaler,* 569 U.S. ----, 133 S.Ct. 1747, 185 L.Ed.2d 783 (2013).
State of TEXAS, plaintiff, v. State of NEW MEXICO and State of Colorado.

No. 141, Original.

Supreme Court of the United States

April 15, 2013.

The Solicitor General is invited to file a brief in this case expressing the views of the United States.
EXHIBIT 15(b)







Texas Utilities Electric Company:

We have made a review, in accordance with standards established by the
American Institute of Certified Public Accountants, of the unaudited condensed
consolidated interim financial information of Texas Utilities Electric Company
and subsidiaries ("TU Electric") for the periods ended June 30, 1998 and 1997,
as indicated in our report dated August 13, 1998; because we did not perform
an audit, we expressed no opinion on that information.

We are aware that our report referred to above, which is included in TU
Electric's Quarterly Report on Form 10-Q for the quarter ended June 30, 1998,
is incorporated by reference in Registration Statements No. 33-69554 and
333-42985  on Form S-3, and Registration Statement No. 33-83976 on Post
Effective Amendment No. 1 to Form S-3, of Texas Utilities Electric Company.

We also are aware that the aforementioned report, pursuant to Rule 436(c)
under the Securities Act of 1933, is not considered a part of the Registration
Statement prepared or certified by an accountant or a report prepared or
certified by an accountant within the meaning of Sections 7 and 11 of that
Act.


DELOITTE & TOUCHE  LLP

Dallas, Texas
August 13, 1998
[Federal Register Volume 60, Number 90 (Wednesday, May 10, 1995)]
[Notices]
[Page 24848]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 95-11437]



-----------------------------------------------------------------------

DEPARTMENT OF ENERGY
[Docket No. RP95-269-000]


Paiute Pipeline Co.; Notice of Proposed Changes in FERC Gas 
Tariff

May 4, 1995.
    Take notice that on May 2, 1995, Paiute Pipeline Company (Paiute), 
tendered for filing to be a part of its FERC Gas Tariff, Second Revised 
Volume No. 1-A, the following tariff sheets, to become effective June 
1, 1995:

First Revised Sheet No. 22
First Revised Sheet No. 51
First Revised Sheet No. 81
Third Revised Sheet No. 161

    Paiute states that it is submitting the proposed tariff sheets in 
order to implement an element of a settlement agreement recently 
reached by the active parties with respect to Paiute's pending tariff 
filing in Docket No. RP95-55-000. According to Paiute, as part of that 
resolution, the parties have agreed to a realignment of the firm 
shippers' summer period monthly billing determinants over a period of 
several years, including the summer period for 1995. Paiute indicates, 
however, that because its customers' monthly billing determinants are 
treated as their contract entitlements, the revised billing 
determinants agreed to by the firm shippers for the 1995 summer period 
need to be filed and made effective immediately.
    Paiute states, therefore, that it is submitting the proposed tariff 
sheets to reflect the agreed-upon billing determinants to be in effect 
as of June 1995, and to revise certain tariff language to correspond to 
the changes in billing determinants.
    Paiute states that copies of the filing were served upon all of 
Paiute's customers and affected state regulatory commissions, and upon 
all parties on the service list in Docket No. RP95-55-000.
    Any person desiring to be heard or to protest said filing should 
file a motion to intervene or a protest with the Federal Energy 
Regulatory Commission, 825 North Capitol Street, NE., Washington, DC 
20426, in accordance with Rules 211 and 214 of the Commission's Rules 
of Practice and Procedure (18 CFR 385.211 and 385.214). All such 
motions or protests should be filed on or before May 11, 1995. Protests 
will be considered by the Commission in determining the appropriate 
action to be taken, but will not serve to make protestants parties to 
the proceeding.
    Any person wishing to become a party must file a motion to 
intervene. Copies of this filing are on file with the Commission and 
are available for public inspection in the public reference room.
Lois D. Cashell,
Secretary.
[FR Doc. 95-11437 Filed 5-9-95; 8:45 am]
BILLING CODE 6717-01-M
Sivatharan NATKUNANATHAN, petitioner, v. UNITED STATES.

No. 12M106.

Supreme Court of the United States

April 15, 2013.

Motion to direct the Clerk to file a petition for writ of certiorari out of time denied.
2021

FANM NAN ESÈS KLINIK

= ESPWA

FANM NAN ESÈS KLINIK (HAITIAN CREOLE)

Esè klinik yo se etid rechèch ki ede montre 

si yon tès oswa yon tretman ap travay epi 

san danje. Gen plizyè fason ou ka patisipe 

nan yon esè. Kèk esè mande ou kesyon sou 

tretman ou deja pran. Nan lòt esè, ou pran 

yon nouvo dwòg. Kèk esè klinik itilize moun 

ki an bon sante. Gen lòt ki itilize moun ki gen 

yon pwoblèm sante espesifik.

Èske Fanm Nan Esè Klinik?

Wi. Fanm yo deja nan esè klinik yo. Sepandan, fanm ki soti nan divès orijin toujou bezwen 

patisipe. Fi ki gen tout laj, rasyal ak gwoup etnik, ak fanm ki gen andikap oswa kondisyon 

sante kwonik ta dwe reflechi rantre nan yon esè klinik.

Ou ka ede le ou konsidere yon ese pou tet ou. Ou ka fe yon diferans le ou ede dokte aprann plis 

sou sante fanm. 

Poukisa Fanm Ta Dwe Patisipe?

Pwodwi medikal ka afekte gason ak fanm yon fason diferan. Li enpòtan pou fanm 

patisipe paske fanm pafwa gen diferan efè segondè. Kò yon fanm kapab afekte tou ki jan 

dwòg ak aparèy travay.

Mande founisè swen 

sante ou si yon esè 

klinik bon pou ou. 

Biwo FDA nan Sante Fanm 

www.fda.gov/womeninclinicaltrials
15 Bagay Ou Ta Dwe Konnen Anvan 

Ou Rantre Nan Yon Esè Klinik

Lè ou nan yon esè klinik se chwa ou. Ou pa ta dwe santi presyon pou ou rantre nan li. 

Ou gen dwa kite nenpòt lè. Gen règ pou pwoteje moun nan esè klinik yo.

Konsantman enfòme se pwosesis pou aprann enfòmasyon enpotan sou esè klinik la 

anvan ou rantre nan li. Lis sa a se pa tout bagay ou bezwen konnen, men li pral ede 

w kòmanse konvèsasyon an. Asire ke tout kesyon ou reponn anvan ou dakò patisipe. 

Chache konnen:

Objektif La Ak Sa Ki Pral Rive

1. Objektif etid la

2. Dwòg, tès, ak tretman ou ka resevwa

3. Konbyen tan etid la ap dire ak konbyen fwa 

wap genyen pou vini

4. Ki jan yo pral kenbe enfòmasyon ou prive

5. Kisa k ap pase lè etid la fini

Risk Ak Benefis Posib Yo

Ese a ka bay tretman oswa tès depistaj, men pa 

gen okenn pwomès ke sante ou ap vin pi bon. 

Medikaman, tès, oswa tretman ka pa travay pou 

ou.

6. Benefis tretman yo

7. Risk ak efè segondè tretman yo

8. Nenpòt tretman oswa lòt opsyon pou 

moun ki gen menm maladi ou an

9. Si ou ka pran lòt medikaman ou yo

Nenpòt Lòt Sipò Oswa Depans 

Posib

10. Ki tretman oswa sèvis etid la ap peye pou 

11. Si etid la ofri swen pou timoun oswa 

 transpò

12. Depans ou ka oblije peye

13. Kisa asirans ou pral kouvri

Kòman Ou Kapab Jwenn Plis 

Enfòmasyon

14. Ki moun ou ta dwe kontakte si ou gen 

kesyon oswa pwoblèm

15. Ki jan ou pral jwenn rezilta yo

Ki Wòl FDA a?

US Food and Drug Administration (FDA) asire tretman medikal san danje epi efikas pou 

moun itilize. FDA pa devlope nouvo tretman oswa fè esè klinik. 

Biwo FDA nan Sante Fanm lan ap fè patenarya ak Biwo Rechèch NIH sou Sante Fanm 

sou yon inisyativ pou ankouraje patisipasyon divès fanm nan esè klinik yo. Pou aprann 

plis sou aktivite sa yo, ale nan: 

www.fda.gov/womeninclinicaltrials
EXHIBIT 13.1





CERTIFICATION PURSUANT TO


18 U.S.C. Section 1350,


AS ADOPTED PURSUANT TO


SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002








In connection with the Annual Report of Seven Arts Pictures plc (the “Group”) on Form 20-F for the period ended June 30, 2011 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), Peter Hoffman, Chief Executive Officer and Principal Financial Officer of the Group, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:





1.
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and





2.
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Group.





Date:  December 21, 2011
By:
/s/ PETER HOFFMANPeter Hoffman

Chief Executive Officer and

Principal Financial Officer








A signed original of this written statement required by 18 U.S.C. Section 1350 has been provided to the Group and will be retained by the Group and furnished to the Securities and Exchange Commission or its staff upon request.
Danetta Lynese SIMPSON, petitioner, v. JP MORGAN CHASE BANK, N.A., as Trustee, et al.

No. 12-9462.

Supreme Court of the United States

June 3, 2013.

Petition for writ of certiorari to the Supreme Court of Michigan denied.

Justice ALITO took no part in the consideration or decision of this petition.
CITY OF TOMBSTONE, ARIZONA, petitioner, v. UNITED STATES, et al.

No. 12-1069.

Supreme Court of the United States

April 15, 2013.

Petition for writ of certiorari to the United States Court of Appeals for the Ninth Circuit denied.
<PAGE>
                                                                               .
                                                                               .
                                                                               .
                                                                      Exhibit 12


                          TEXTRON FINANCIAL CORPORATION
    STATEMENT SETTING FORTH COMPUTATION OF RATIO OF EARNINGS TO FIXED CHARGES

<TABLE>
<CAPTION>
                                                                                                                SIX MONTHS ENDED
                                                                                                                  JUNE 30, 2003
<S>                                                                                                             <C>
(DOLLARS IN THOUSANDS)

Income before income taxes, distributions on preferred securities
  and cumulative effect of change in accounting principle...................................................        $   50,390
                                                                                                                    ----------
FIXED CHARGES:
Interest on debt............................................................................................            92,499
Estimated interest portion of rents.........................................................................             1,533
                                                                                                                    ----------
Total fixed charges.........................................................................................            94,032
                                                                                                                    ----------
Adjusted Income.............................................................................................           144,422
Ratio of earnings to fixed charges (1)......................................................................             1.54x
                                                                                                                    ==========
</TABLE>

(1) The ratio of earnings to fixed charges has been computed by dividing income
before income taxes, distributions on preferred securities and cumulative effect
of change in accounting principle and fixed charges by fixed charges. Fixed
charges consist of interest on debt and one-third rental expense as
representative of interest portion of rentals.
1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

United States District Court

Northern District of California

UNITED STATES DISTRICT COURT

NORTHERN DISTRICT OF CALIFORNIA

WAYMO LLC,

Plaintiff,

v.

UBER TECHNOLOGIES, INC., et al.,

Defendants.

Case No.17-cv-00939-WHA (JSC)

ORDER GRANTING IN PART

DEFENDANTS’ MOTION FOR A 

FURTHER DEPOSITION OF PIERRE 

DROZ

Re: Dkt. No. 1121

Pierre Droz was and is Waymo’s technical lead for Waymo’s LIDAR team. After Uber 

noticed his deposition in his individual capacity, Waymo designated him as its 30(b)(6) witness on 

many of the technical issues in this trade secret and patent case. Uber took his deposition for 

seven hours and seeks an additional seven hours. Otto Trucking seeks an additional seven hours, 

for a total of 14 additional hours. The Court finds that Defendants have shown good cause for an 

additional seven hours of deposition testimony as Mr. Droz is one of Waymo’s most important 

witnesses in this case. Further, Waymo does not dispute that they designated Mr. Droz as their 

30(b)(6) corporate witness the night before his deposition. This was not enough notice to allow 

Defendants to coordinate how they would use their deposition time. The Court declines, however, 

to order Mr. Droz to sit for an additional two days of deposition. Uber and Otto Trucking’s 

interests are aligned and they have not shown why an additional seven hours is insufficient to 

complete the needed deposition testimony. Defendants shall divide the seven hours between 

themselves at their discretion. Waymo shall make Mr. Droz available for deposition on or before 

the close of fact discovery. Further, if Defendants intend to question Mr. Droz as to 30(b)(6) 

topics on which Waymo has designated him, they shall advise Waymo of those topics at the time 

Mr. Droz’s deposition is scheduled.
2

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

United States District Court

Northern District of California

Any objections to this Order must be filed with the district court on or before the close of 

business on August 16, 2017. In the meantime the parties shall schedule Mr. Droz’s continued 

deposition.

This Order disposes of Docket No. 1121.

IT IS SO ORDERED.

Dated: August 15, 2017

JACQUELINE SCOTT CORLEY

United States Magistrate Judge
Presidential Documents

21971

Federal Register

Vol. 60, No. 85

Wednesday, May 3, 1995

Title 3—

The President

Proclamation 6794 of April 29, 1995

Loyalty Day, 1995

By the President of the United States of America

A Proclamation

Our country’s rich diversity of peoples and cultures has been called ‘‘the

noble experiment.’’ From its beginnings, our great democracy has guaranteed

its citizens the blessings of freedom and the right of self-determination.

Each year, with the coming of spring and the rebirth of nature, we pause

to consider the progress of our Nation and to reaffirm our allegiance to

the American experiment.

Two hundred and twenty years ago in Lexington, Massachusetts, a ragged

group of colonial Americans faced a column of British soldiers. As the

smoke cleared from the ‘‘shot heard round the world,’’ eight American

‘‘Minutemen’’ lay dead-their blood spilled along the path to a new Nation

on this soil. Their gift of freedom is held sacred to this day.

All Americans can be proud of the heritage of courage and sacrifice that

has extended unbroken through generations of our citizens. The success

of the United States today is seen both in our continued prosperity and

strength and in our role as an international beacon of liberty. As we recall

those who gave their lives for our freedom, we see our Nation’s history

reflected in their ranks-from the tireless ‘‘Minutemen’’ in Lexington to the

brave men and women who fought in the Persian Gulf. These fine citizens,

along with their families and those who have served on the home front,

deserve our profound respect and gratitude. Let history forever record our

loyalty to their legacy.

The Congress, by Public Law 85–529, has designated May 1 of each year

as ‘‘Loyalty Day.’’ We spend this day in celebration of our Constitution

and our precious Bill of Rights and in honor of the sacrifices that have

enabled this great charter to endure.

NOW, THEREFORE, I, WILLIAM J. CLINTON, President of the United States

of America, do hereby proclaim May 1, 1995, as Loyalty Day. I call upon

all Americans to observe this day with appropriate ceremonies and activities,

including public recitation of the Pledge of Allegiance to the Flag of the

United States. I also call upon government officials to display the flag

on all government buildings and grounds on this day.

IN WITNESS WHEREOF, I have hereunto set my hand thistwenty-ninth

day of April, in the year of our Lord nineteen hundred and ninety-five,

and of the Independence of the United States of America the two hundred

[FR Doc. 95–11089

Filed 5–1–95; 4:36 pm]

Billing code 3195–01–P

and nineteenth.

œ–
Jeremy Ryan HADDIX, petitioner, v. TEXAS, et al.

No. 12-7076.

Supreme Court of the United States

April 1, 2013.

Petition for rehearing denied.
Ricky Douglas HAYNES, Jr., petitioner, v. UNITED STATES.

No. 12-9115.

Supreme Court of the United States

April 15, 2013.

Petition for writ of certiorari to the United States Court of Appeals for the Eleventh Circuit denied.
Joseph HARRIS, Doc #364597, Appellant, v. STATE of Florida, Appellee.

Case No. 2D18-3571

District Court of Appeal of Florida, Second District.

Opinion filed July 12, 2019

**DECISION WITHOUT PUBLISHED OPINION**

Affirmed.
November 12, 2019

Cynthia Philips, Ph.D.

V.P. of Regulatory and Clinical Affairs

BioFire Defense, LLC

79 West 4500 South Suite 14

Salt Lake City, Utah 84107, US 

Re: EUA140010/A003

Trade/Device Name: FilmArray Biothreat-E

Dated: June 4, 2019

Received: June 13, 2019

Dear Dr. Philips:

This letter is to notify you that your request to modify the authorized Instructions for Use of the FilmArray 

Biothreat-E test to include additional data on analytical exclusivity wet-testing and inclusion of associated 

limitations has been granted. In addition, the updates requested by the US Food and Drug Administration

(FDA) to the (1) Instructions for Use, including wording in the intended use, to improve the overall clarity 

and accuracy of the document, and (2) Healthcare Provider and Patient Fact Sheets, have been granted.

Upon review, we concur that the data submitted in EUA140010/A003 supports the addition of the 

aforementioned data to the Instructions for Use. By submitting this amendment for review by the FDA, you 

have complied with the Conditions of Authorization stated in the letter authorizing the emergency use of 

the FilmArray Biothreat-E test issued on October 25, 2014.

Sincerely yours,

Uwe Scherf, M.Sc., Ph.D.

Director

Division of Microbiology Devices

OHT7: Office of In Vitro Diagnostics

 and Radiological Health

Center for Devices and Radiological Health
*Pursuant to Local Rule 47.5, the Court has determined that

this opinion should not be published and is not precedent except

under the limited circumstances set forth in Local Rule 47.5.4.

IN THE UNITED STATES COURT OF APPEALS

FOR THE FIFTH CIRCUIT

 

No. 96-60108

 

UNITOG RENTAL SERVICES, INC.,

Respondent,

versus

NATIONAL LABOR RELATIONS BOARD,

Petitioner.

 

Appeal from the United States District Court for the

Northern District of Texas

(16-CA-14380)

 

December 9, 1996

Before REAVLEY, GARWOOD and BENAVIDES, Circuit Judges.*

PER CURIAM:

The cross-application of the National Labor Relations Board

for enforcement of the order of the National Labor Relations Board

is GRANTED, and Unitog Rental Services, Inc.’s petition for review

of the order of the National Labor Relations Board is DENIED.
피부 제품 안전:

하이드로퀴논

하이드로퀴논 성분을 함유하는 피부 미백 제품은 유해할 수 있습니다.

안전하게 지내세요!

면허가 있는 의료 서비스 제공자가 처방한 경우에만 

하이드로퀴논이 함유된 피부 제품을 사용하십시오. 

처방전이 없이 피부 제품을 구입하거나 사용하기 전에 

제품 라벨에서 하이드로퀴논을 확인하십시오.

ૺࢼ؏ײْ଑

ଡۉଜߛ߂߇лଢ߻

고르지 않은 피부 톤 교정 

어두운 반점, 잡티, 주름 제거

www.fda.gov/SkinFacts를 방문하여 피부 제품 

안전에 대한 피부 관련 사실을 얻으십시오! 

하이드로퀴논은 다음과 같은 용도로 

사용되는 피부 미백 제품의 활성 성분

입니다.

영구적일 수 있는 피부 변색(조직

흑갈병)

발진

얼굴 붓기

이러한 제품의 사용으로 인한 

심각한 부작용이보고되었습니다.

알고 

계셨습니까?

하이드로퀴논을 함유한 피부 

미백 제품은 FDA가 미국에서 처방전 없이 

판매하는 행위에 대해 승인하지 않았습니다. 
피부 제품 안전: 수은

수은 성분을 함유한 피부 미백 제품은 유해할 수 있습니다.

ૺࢼ؏ײْ଑

ଡۉଜߛ߂߇лଢ߻

www.fda.gov/SkinFacts를 방문하여 피부 제품 

안전에 대한 피부 관련 사실을 얻으십시오! 

알고 

계셨습니까?

FDA는 피부 미백 제품에 수은의

사용을 금지했습니다. 

수은을 함유한 피부 제품을 

사용하면 다음과 같은 심각한 건강 

문제가 발생할 수 있습니다.

눈, 폐 및 신장 손상, 

소화기, 면역 및 신경계의 손상

피부 발진 및 감염

갈색 회색 피부 변색

Ingredients: Linalool,

Aqua, Glycerin, Parfum,

Isomethyl Ionone,

Calomel, Xanthan,

Hydrogenated Veg Oil.

수은 중독은 또한 혼수 상태와 심지어 

사망을 초래할 수 있습니다.

이러한 성분이 함유된 제품을 

사용하거나 구매하지 마십시오.

수은을 식별하는 용어는 제품 성분 

라벨을 확인하십시오.

수은 염화물 

칼로멜

수은

머큐리오

Hg

독극물 관리국에 (Poison 

Control)1-(800)-222-1222

번으로 연락하여 즉시

의료 서비스 제공자에게 

연락하십시오.

수은과 접촉한 손과 몸의 

기타 부분을 철저히 

씻으십시오.

지역 유해 폐기물 센터에서 

수은이 함유된 피부 제품을 

폐기하십시오.

귀하 또는 가족 중 누군가가 수은에 노출된 경우 : 

Ingredients: Linalool, 

Aqua, Glycerin, Parfum, 

Isomethyl Ionone, 

Calomel, Xanthan,

Hydrogenated Veg Oil.

Ingredients: Lina

Aqua, Glycerin, Pa

Isomethyl Ionone, 

Calomel, Xanthan

Hydrogenated Ve
라벨, 수제 라벨이 없거나 또는 영어로 작성되지 않은 라벨이 있는 제품은 피하십시오.

피부 제품 안전:

FDA 안전하지 않은 제품 식별

하이드로퀴논 또는 수은 성분을 함유하는 피부 미백 제품은 해를 끼칠 수 

있습니다. 처방전 없이 이러한 제품의 판매는 미국에서 불법입니다. 구매하기 

전에 피부 제품 라벨을 읽고 성분을 확인하십시오.

ૺࢼ؏ײْ଑

ଡۉଜߛ߂߇лଢ߻

www.fda.gov/SkinFacts를 방문하여 피부 제품 

안전에 대한 피부 관련 사실을 얻으십시오!

피부 미백 비누 

스킨 이브닝 로션

피부 미백 파우더

스팟 보정 크림

화학 박피

주의 

FDA는 하이드로퀴논 또는 수은을 함유한 

화장품 및 비처방(처방전 없이 구매) 피부 

제품의 사용으로 인한 심각한 부작용에 대한 

보고를 받았습니다. 이러한 제품의 판매는 

미국에서 불법입니다.

확인

피부 미백 제품은 다음과 같은 문구로 확인할 

수 있습니다.

검사

피부 미백제를 구입하거나 사용하기 전에 

제품, 라벨을 확인하여 하이드로퀴논 또는 

수은이 함유되어 있는지 확인하십시오.

수은은 또한 다음과 같이 나열될 수 있습니다:

다음과 같은 피부 상태를 치료하려면: 

기미

주근깨 

여드름

주름

수은 염화물

칼로멜

수은

머큐리오

Hg

FDA는 이러한 제품의 사용에 대해 조언하고 소비자가 

치료 옵션에 대해 의료 서비스 제공자와 상담할 것을 

권장합니다.